Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01493011

Chemotherapy Combined With Whole-body Hyperthermia to Treat Stage IIIB/IV Non Small Cell Lung Cancer — WBH&NSCLC  

Non-small Cell Lung Cancer Stage IIIB Clinical Trial

Official title:
A Randomized Contrasted Polycentric Clinical Study About Chemotherapy Combined With Whole-body Hyperthermia(WBH)to Treat Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)

Clinical Trial Summary

Millions of patients die of non-small cell lung cancer (NSCLC) every year. There are several methods to treat NSCLC, including surgery, chemotherapy, radiotherapy and bioimmuotherapy. Recently, hyperthermia therapy has played an important role in neoplasm therapy. It has showed some effect in NSCLC both in animal experiment and clinical practice, yet there is little literature about Whole-body Hyperthermia (WBH) with neoplasm. The investigators decides to develop this randomized contrasted multicenter clinical study to testify to the effect of chemotherapy combined with WBH to treat stage IIIB/IV Non Small Cell Lung Cancer (NSCLC).

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01493011
Study type Interventional
Source Xijing Hospital
Contact LIU WENCHAO, professor
Phone 029-84775407
Email liuch@FMMU.edu.cn
Status Recruiting
Phase N/A
Start date November 2011
Completion date December 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02035683 - PET/CT Scan as a Tool to Rationalize the Treatment of of Advanced NSCLC Patients Undergoing First Chemotherapy N/A
Terminated NCT00766246 - Phase II Avastin Trial for Stage IIIB/IV NSCLC Phase 2
Terminated NCT03386929 - Survival Prolongation by Rationale Innovative Genomics Phase 1/Phase 2
Not yet recruiting NCT06394427 - Neoadjuvant Chemoimmunotherapy in Stage IIIA- N2IIIB Non-small Cell Lung Cancer
Terminated NCT01348126 - Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer Phase 2/Phase 3
Recruiting NCT05919264 - FOG-001 in Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05713006 - Alectinib Pharmacokinetic in Patients With NSCLC Phase 1/Phase 2
Terminated NCT01798485 - A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC Phase 3
Active, not recruiting NCT01405586 - MILES-3: Cisplatin in Combination With Gemcitabine for Elderly Patients With Lung Cancer Phase 3
Withdrawn NCT03628144 - Immunonutrition to Reduce Toxicities in Non-Small Cell Lung Cancer Phase 2
Completed NCT02176369 - Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA Trial Phase 2
Active, not recruiting NCT03611738 - Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC Phase 1
Completed NCT01473563 - A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) Phase 2
Active, not recruiting NCT01656551 - MILES-4: Study Comparing Gemcitabine and Pemetrexed, With or Without Cisplatin, in Patients With Nonsquamous Lung Cancer Phase 3
Not yet recruiting NCT03543683 - Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC
Not yet recruiting NCT03532698 - Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)